Management

The management team at Bridge Biotherapeutics, Inc. has in-depth experience in the global pharmaceutical industry. With their multiple decades of combined professional experience, The Bridge Biotherapeutics team has been successfully developing early stage assets to clinic and is expected to expand and strengthen its pipeline to address global unmet medical needs.

• James Jungkue Lee

  CEO

  more
  James Jungkue Lee founded Bridge Biotherapeutics, Inc. in 2015 and currently serves as CEO. After receiving his M.S. in Structural Biology from Seoul National University, he took various roles in research, research planning, and business development at LG Chem. James co-founded Crystal Genomics and led fundraising and business development. In 2008, he founded Rex Bio and successfully developed an antibody treatment for pancreatic cancer.
• Sang-Uk Kang

  Senior Vice President, R&D / Ph.D.

  more
  Sang-Uk Kang serves as Senior Vice President of Research and Development. After receiving his Ph.D. in Pharmacy at Seoul National University, he had post-doctoral training at the National Cancer Institute, in US in the area of anti-cancer drugs and antibiotics. Sang-Uk had been involved in discovery of anti-cancer and hepatitis C drugs in Rexahn and Sequoia, biotech companies located in Maryland. Prior to joining Bridge Biotherapeutics, he served as General Manager in new business development, medicinal chemistry, and CMC at Chemizon (now CMG Pharmaceuticals), Bukwang Pharmaceuticals, and Yuyu Pharmaceuticals.
• Gwanghee Lee

  Senior Vice President, Research / Ph.D.

  more
  Gwanghee Lee serves as Senior Vice President and Head of Translational Research. After receiving his B.S. and M.S. from Seoul National University, he earned a Ph.D. in Life Science from Washington University in St. Louis and postdoctoral training at the National Institute of Health and Genentech in the U.S. Prior to joining Bridge Biotherapeutics. He served as Project Leader of anti-cancer pipelines and Director of Korea Research Institute in Sanofi.
• Taeksang Park

  Vice President, Chief Financial Officer / AICPA

  more
  Prior to joining Bridge Biotherapeutics, Taeksang served as Manager of Finance Team at KT Commerce for 10 years where he was in charge of accounting, tax, funding, and internal controls. He also led overseas business/investment, IPO, IR, KOSDAQ registration planning, business valuation, and stock issuance at S-TEC System and Kukil Paper.